JP2022548688A5 - - Google Patents
Info
- Publication number
- JP2022548688A5 JP2022548688A5 JP2022517369A JP2022517369A JP2022548688A5 JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5 JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022517369 A JP2022517369 A JP 2022517369A JP 2022548688 A5 JP2022548688 A5 JP 2022548688A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- disease
- hydroxypropyl methylcellulose
- bms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025124835A JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Ｔｙｋ２阻害薬の徐放性剤形 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902218P | 2019-09-18 | 2019-09-18 | |
| US62/902,218 | 2019-09-18 | ||
| PCT/US2020/051341 WO2021055651A1 (en) | 2019-09-18 | 2020-09-18 | Extended release dosage forms for tyk2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025124835A Division JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Ｔｙｋ２阻害薬の徐放性剤形 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022548688A JP2022548688A (ja) | 2022-11-21 |
| JP2022548688A5 true JP2022548688A5 (https=) | 2023-09-27 |
| JP7719770B2 JP7719770B2 (ja) | 2025-08-06 |
Family
ID=72670853
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517368A Active JP7812785B2 (ja) | 2019-09-18 | 2020-09-18 | Ｔｙｋ２阻害薬の剤形 |
| JP2022517369A Active JP7719770B2 (ja) | 2019-09-18 | 2020-09-18 | Ｔｙｋ２阻害薬の徐放性剤形 |
| JP2025124835A Pending JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Ｔｙｋ２阻害薬の徐放性剤形 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517368A Active JP7812785B2 (ja) | 2019-09-18 | 2020-09-18 | Ｔｙｋ２阻害薬の剤形 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025124835A Pending JP2025163082A (ja) | 2019-09-18 | 2025-07-25 | Ｔｙｋ２阻害薬の徐放性剤形 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US12521390B2 (https=) |
| EP (3) | EP4031109B1 (https=) |
| JP (3) | JP7812785B2 (https=) |
| KR (2) | KR20220066310A (https=) |
| CN (8) | CN114727949A (https=) |
| AU (1) | AU2020348783B2 (https=) |
| BR (2) | BR112022004216A2 (https=) |
| CA (2) | CA3151137A1 (https=) |
| DK (1) | DK4031110T3 (https=) |
| ES (1) | ES3060149T3 (https=) |
| FI (1) | FI4031110T3 (https=) |
| HR (1) | HRP20260058T1 (https=) |
| IL (2) | IL291452A (https=) |
| LT (1) | LT4031110T (https=) |
| MX (4) | MX2022003150A (https=) |
| PL (1) | PL4031110T3 (https=) |
| PT (1) | PT4031110T (https=) |
| RS (1) | RS67803B1 (https=) |
| SI (1) | SI4031110T1 (https=) |
| WO (2) | WO2021055651A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| IL301389A (en) * | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
| CA3208361A1 (en) | 2021-02-19 | 2022-08-25 | Anjali Pandey | Tyk2 inhibitors and uses thereof |
| EP4294806A1 (en) | 2021-02-19 | 2023-12-27 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| AU2022222470A1 (en) | 2021-02-19 | 2023-09-21 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| EP4404930A1 (en) | 2021-09-23 | 2024-07-31 | Bristol-Myers Squibb Company | Methods of treating hair-loss disorders with tyk2 inhibitors |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| JP2024539703A (ja) * | 2021-10-28 | 2024-10-29 | ブリストル－マイヤーズ スクイブ カンパニー | デュークラバシチニブの局所製剤 |
| WO2023181075A1 (en) * | 2022-03-24 | 2023-09-28 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersions of deucravacitinib and processes for the preparation thereof |
| AR128868A1 (es) * | 2022-03-25 | 2024-06-19 | Nimbus Lakshmi Inc | Formulaciones de inhibidor de tyk2 y métodos para elaborarlas |
| WO2024176263A1 (en) * | 2023-02-22 | 2024-08-29 | Cipla Limited | Deucravacitinib amorphous solid dispersions and polymorphs thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2287971T3 (es) * | 1997-08-11 | 2007-12-16 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas con biodisponibilidad incrementada. |
| ATE400251T1 (de) * | 1999-02-09 | 2008-07-15 | Pfizer Prod Inc | Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| ATE404178T1 (de) | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
| EP1967185A1 (en) | 1999-12-23 | 2008-09-10 | Pfizer Products Inc. | Hydrogel-driven drug dosage form |
| JP2004534812A (ja) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
| CN1625397A (zh) | 2002-02-01 | 2005-06-08 | 辉瑞产品公司 | 胆固醇酯转移蛋白抑制剂的控制释放药物剂型 |
| US20090011018A1 (en) | 2006-12-28 | 2009-01-08 | Astellas Pharma Inc., | Sustained release formulation for tacrolimus |
| CN101152158B (zh) | 2007-08-21 | 2010-05-26 | 浙江大学 | 一种药物的双层芯渗透泵片的制备方法 |
| SMT202000093T1 (it) | 2009-06-16 | 2020-03-13 | Pfizer | Forme di dosaggio di apixaban |
| EP2734190A1 (en) | 2011-07-21 | 2014-05-28 | Bristol-Myers Squibb Company | Bioavailable compositions of amorphous piperidinyl compounds |
| JP6404217B2 (ja) * | 2012-09-11 | 2018-10-10 | メディベイション プロステイト セラピューティクス エルエルシー | エンザルタミドの製剤 |
| EP2895150A1 (en) | 2012-09-11 | 2015-07-22 | Bend Research, Inc. | Methods for making pharmaceutical solid dosage forms of spray-dried dispersions |
| JP2015531365A (ja) * | 2012-09-28 | 2015-11-02 | オンコエシックス エスエー | チエノトリアゾロジアゼピン化合物を含む医薬製剤 |
| LT3495358T (lt) * | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| US9895308B2 (en) | 2013-03-14 | 2018-02-20 | Amgen Inc. | Heterocyclic compounds and their uses |
| JP7113023B2 (ja) | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| KR102848769B1 (ko) | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| JP7812785B2 (ja) * | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| IL301389A (en) * | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
-
2020
- 2020-09-18 JP JP2022517368A patent/JP7812785B2/ja active Active
- 2020-09-18 ES ES20781719T patent/ES3060149T3/es active Active
- 2020-09-18 CA CA3151137A patent/CA3151137A1/en active Pending
- 2020-09-18 PL PL20781719.8T patent/PL4031110T3/pl unknown
- 2020-09-18 EP EP20781718.0A patent/EP4031109B1/en active Active
- 2020-09-18 CN CN202080078646.5A patent/CN114727949A/zh not_active Withdrawn
- 2020-09-18 WO PCT/US2020/051341 patent/WO2021055651A1/en not_active Ceased
- 2020-09-18 HR HRP20260058TT patent/HRP20260058T1/hr unknown
- 2020-09-18 LT LTEPPCT/US2020/051342T patent/LT4031110T/lt unknown
- 2020-09-18 CN CN202411436266.0A patent/CN119424434A/zh active Pending
- 2020-09-18 JP JP2022517369A patent/JP7719770B2/ja active Active
- 2020-09-18 WO PCT/US2020/051342 patent/WO2021055652A1/en not_active Ceased
- 2020-09-18 CN CN202411691316.XA patent/CN119745885A/zh active Pending
- 2020-09-18 CN CN202411662444.1A patent/CN119700772A/zh active Pending
- 2020-09-18 EP EP25216739.0A patent/EP4706778A2/en active Pending
- 2020-09-18 KR KR1020227012286A patent/KR20220066310A/ko active Pending
- 2020-09-18 CN CN202411436265.6A patent/CN119424433A/zh active Pending
- 2020-09-18 AU AU2020348783A patent/AU2020348783B2/en active Active
- 2020-09-18 CN CN202080078644.6A patent/CN114727948A/zh not_active Withdrawn
- 2020-09-18 BR BR112022004216A patent/BR112022004216A2/pt unknown
- 2020-09-18 MX MX2022003150A patent/MX2022003150A/es unknown
- 2020-09-18 FI FIEP20781719.8T patent/FI4031110T3/fi active
- 2020-09-18 KR KR1020227012287A patent/KR20220066105A/ko active Pending
- 2020-09-18 CA CA3151369A patent/CA3151369A1/en active Pending
- 2020-09-18 SI SI202030709T patent/SI4031110T1/sl unknown
- 2020-09-18 CN CN202411443114.3A patent/CN119424435A/zh active Pending
- 2020-09-18 PT PT207817198T patent/PT4031110T/pt unknown
- 2020-09-18 MX MX2022003146A patent/MX2022003146A/es unknown
- 2020-09-18 EP EP20781719.8A patent/EP4031110B1/en active Active
- 2020-09-18 CN CN202411670975.5A patent/CN119700773A/zh active Pending
- 2020-09-18 RS RS20260116A patent/RS67803B1/sr unknown
- 2020-09-18 US US17/639,481 patent/US12521390B2/en active Active
- 2020-09-18 US US17/639,489 patent/US20230255964A1/en active Pending
- 2020-09-18 DK DK20781719.8T patent/DK4031110T3/da active
- 2020-09-18 BR BR112022004550A patent/BR112022004550A2/pt unknown
-
2022
- 2022-03-15 MX MX2025014307A patent/MX2025014307A/es unknown
- 2022-03-15 MX MX2025014308A patent/MX2025014308A/es unknown
- 2022-03-16 IL IL291452A patent/IL291452A/en unknown
- 2022-03-16 IL IL291453A patent/IL291453A/en unknown
-
2025
- 2025-07-25 JP JP2025124835A patent/JP2025163082A/ja active Pending
- 2025-12-02 US US19/406,929 patent/US20260083734A1/en active Pending
- 2025-12-02 US US19/406,921 patent/US20260083733A1/en active Pending